Page last updated: 2024-12-06

iproclozide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iproclozide is a tricyclic antidepressant (TCA) that was developed in the 1960s. It was marketed under the brand name Luvox in some countries. Iproclozide is a potent inhibitor of the enzyme monoamine oxidase (MAO), particularly MAO-A. This inhibition leads to increased levels of neurotransmitters such as serotonin, norepinephrine, and dopamine in the brain. Iproclozide has been shown to have antidepressant effects in clinical trials, but it has also been associated with a number of side effects, including drowsiness, dizziness, and dry mouth. Due to its potential for drug interactions and serious side effects, iproclozide is not widely prescribed today. It is still studied for its potential as an antidepressant and for its effects on other neurological conditions, such as anxiety and obsessive-compulsive disorder.'

iproclozide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID19063
CHEMBL ID91238
CHEBI ID134988
SCHEMBL ID49744
SCHEMBL ID20876300
MeSH IDM0055994

Synonyms (48)

Synonym
pc-603
CHEMBL91238
sog-4
einecs 222-589-5
(p-chlorophenoxy)acetic acid 2-isopropylhydrazide
iproclozidum [inn-latin]
(4-chlorophenoxy)acetic acid 2-(1-methylethyl)hydrazide
acetic acid, (p-chlorophenoxy)-, 2-isopropylhydrazide
acetic acid, (4-chlorophenoxy)-, 2-(1-methylethyl)hydrazide
sinderesin
isopropyl hydrazide de l'acide p-chlorophenoxyacetique [french]
sursum
iproclozide
isopropilidrazide dell'ac. p-cloro-fenossiacetico [italian]
1-(p-chlorophenoxyacetyl)-2-isopropyl hydrazine
p-chlorophenoxyacetic acid 2-isopropylhydrazide
iproclozide [inn:ban:dcf]
brn 2119215
iproclozid
iproclozida [inn-spanish]
iproclozide (tn)
D07338
iproclozide (inn)
3544-35-2
CHEBI:134988
AKOS001592893
2-(4-chlorophenoxy)-n'-propan-2-ylacetohydrazide
2-(4-chlorophenoxy)-n'-isopropylacetohydrazide
isopropilidrazide dell'ac. p-cloro-fenossiacetico
1ii9d6cb3j ,
iproclozidum
isopropyl hydrazide de l'acide p-chlorophenoxyacetique
unii-1ii9d6cb3j
iproclozida
SCHEMBL49744
iproclozide [mi]
iproclozide [mart.]
iproclozide [inn]
iproclozide [who-dd]
DB09247
DTXSID70188925
SR-01000078303-1
sr-01000078303
Q6065438
picrasinb
SCHEMBL20876300
iproclozid; pc 603; pu 603; sursum
2-(4-chlorophenoxy)-n/'-propan-2-ylacetohydrazide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID227700Anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (62.50)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.63 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]